Clinical/Research News From APA’s 2017 Annual Meeting Day One
Welcome to San Diego!
APA’s 2017 Annual Meeting began in San Diego today. From now through May 24, Psychiatric News will deliver an evening digest of some of the day’s highlights—from the lecture halls to the exhibit floor. Whether you are here in San Diego or at home, these reports will convey the excitement and outstanding scientific program being presented at this year’s meeting.
Identity can be a source of both emotional adversity and strength for ethnic minority college students, said speakers at a panel today at APA’s Annual Meeting.
Read More >
Psychiatrists have been at the forefront of encouraging patients to adopt ideas like recovery, resilience, and engagement, yet when confronting their own mental health issues, psychiatrists lean toward privacy. Read More >
Interpretation of transference, treatment of narcissistic personality disorder, and the evolution of psychodynamic treatments for borderline personality disorder and posttraumatic stress disorder were among topics discussed. Read More >
Volkow Honored for Addiction Research
Nora Volkow, M.D., director of the National Institute on Drug Abuse, was presented the Presidential Award for 2017 today by the American Association of Chairs of Departments of Psychiatry. The organization presents the award each year to a psychiatrist for distinguished scientific achievement and leadership in the field of psychiatry. Volkow was honored for her groundbreaking psychiatric research demonstrating drug addiction is a brain disease. She is flanked by Ondria Gleason, M.D., chair of the Department of Psychiatry at the University of Oklahoma School of Community Medicine, and Britta Ostermeyer, M.D., chair of the Department of Psychiatry and Behavioral Sciences at the University of Oklahoma Health Sciences Center.
As interest in digital technologies like smartphones and telemedicine continues to expand in psychiatry, psychiatrists should be aware of the promise and the pitfalls of this digital evolution. Read More >
Ketamine’s ability to relieve symptoms of treatment-resistant depression in a matter of hours has captured the attention of clinicians and patients alike. However, it’s not the only medication on the market capable of exerting rapid antidepressant effects. Read More >
